Fosamax Trial Expert Stumbles Over Report Origins
A health sciences researcher admitted in court that a U.S. Food and Drug Administration report critical of Merck & Co. osteoperosis drug Fosamax had not received an official sign-off by the...To view the full article, register now.
Already a subscriber? Click here to view full article